Treatment of pruritus in dogs associated with allergic dermatitis.
Composition: Oclacitinib maleato
This product is no longer in stock
Treatment of itching associated with allergic dermatitis in dogs.
Treatment of clinical manifestations of atopic dermatitis in dogs.
Do not use in case of hypersensitivity to the active substance or to any excipients.
Do not use in dogs less than 12 months of age or less than 3 kg.
Do not use in dogs with evidence of immunosuppression, as hyperadrenocorticism, or progressive malignancy evident since the active substance has not been evaluated in these cases.
Special Precautions for use in animals: Oclacitinib modulates the immune system and can increase susceptibility to infections and exacerbate neoplastic conditions. Therefore treated dogs APOQUEL tablets should be monitored for the development of infections and neoplasia.
When the itching associated with allergic dermatitis with oclacitinib question, investigate and treat any underlying cause (eg. Allergic flea dermatitis, contact dermatitis, food hypersensitivity). Furthermore, in cases of allergic dermatitis and atopic dermatitis, it is recommended to investigate and treat factors causing complications such as infections / infestations bacterial, fungal or parasitic (eg fleas, scabies).
Debido a su potencial efecto sobre ciertos parametros clinico-patologicos en tratamientos a largo plazo se recomienda la monitorizacion periodica con recuentos sanguineos completos y bioquimica serica.
Precauciones especificas que debe tomar la persona que administre el medicamento veterinario a los animales :Lavar las manos despues de su administracion.
Because of its potential effect on certain clinico-pathological parameters in long-term treatment with periodic monitoring complete blood counts and serum biochemistry is recommended.
Special precautions to be taken by the person administering the veterinary medicinal product to animals: Wash hands after its administration.
Clinico-pathological changes related to treatment: confined to an increase in the average serum cholesterol and a decrease in the mean leukocyte count, however, all mean values remained within the laboratory reference range. The decrease in the mean lymphocyte counts observed in dogs treated with oclacitinib was not progressive, and affection to all types of cells of the white series (count of neutrophils, eosinophils and monocytes), with the exception of lymphocyte count. None of these changes was significant clinically.
Use during gestation, lactation or lay: It has not been demonstrated the safety of the product during gestation, lactation or in breeding dogs, therefore its use is not recommended during gestation, lactation or in breeding dogs .
Dosage: oral route of administration and usage.
Dosage and treatment:
The recommended starting dose is 0.4 to 0.6 mg oclacitinib / kg, administered orally, twice daily for 14 days.
As maintenance therapy should be administered the same dose (0.4 to 0.6 mg oclacitinib / kg) only once a day. Maintenance therapy long term must be based on individual benefit risk assessment.
These tablets can be taken with or without food.
No customer reviews for the moment.